Follow The Filings

MRVI Maravai Lifesciences Holdings

Health Care, filed as MARAVAI LIFESCIENCES HLDGS I (COM CL A), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 2 Owners
  • Max 0.1%
  • $28M
  • 1 add

In 2026 Q2 First Eagle Investment Management added to Maravai Lifesciences.

Who owns this now

Largest portfolio weights among holders, up to 0.1% (First Pacific Advisors). Not free-float ownership.

  1. First Pacific Advisors 0.07%
  2. First Eagle Investment Manage... Add 0.04%

Who owns MRVI

Sorted by value, long equity only, as of 2026 Q2.

History
First Eagle Investment Management 0.04%, was 0.01% Add +45.4% 3,671,287 $23M History
First Pacific Advisors 0.07% Hold 884,883 $5.5M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MRVI's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MRVI insider trades
  • $1.9M bought by 2 insiders
  • None no sales outside a trading plan
  • $254K sold by 1 insider under 10b5-1 plans
  1. Kurt Oreshack General Counsel
    Planned sale
    $254K 50,000 shares at $5.08 13% of stake
    Traded Jun 9–10 Filed Jun 10
    ↗
  2. Gregory T Lucier Director
    Buy
    $369K 100,000 shares at $3.69 +181% to stake
    Traded Dec 5–8 Filed Dec 9, 2025
    ↗
  3. Bernd Brust CEO
    Buy
    $703K 216,212 shares at $3.25 +86% to stake
    Traded Nov 13, 2025 Filed Nov 17, 2025
    ↗
  4. Bernd Brust CEO
    Buy
    $809K 250,559 shares at $3.23 New stake
    Traded Nov 11–12 Filed Nov 13, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 13 share withholdings for taxes, 10 stock grants, and 2 gifts.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,1.02,2.03,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc
DEF 14A Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $288.94M $259.18M $185.74M
Gross profit * $140.2M $108.31M $33.99M
Gross margin * 48.5% 41.8% 18.3%
Net income -$119.03M -$144.85M -$130.77M
Net margin * -41.2% -55.9% -70.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $699.91M $681.5M $296.25M
Total non-current assets * $787.54M $762.25M $474.33M
Total assets $1.49B $1.44B $0.771B
Total current liabilities $87.47M $68.62M $44.92M
Total non-current liabilities * $610.1M $602.64M $352.95M
Total equity $416.75M $434.73M $212.38M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $126.22M $7.46M -$57.57M
Cash from investing -$122.31M -$24.32M -$31.4M
Cash from financing -$61.09M -$235.71M -$16.5M
Net change in cash -$57.18M -$252.56M -$105.51M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.